2013, Number 2
<< Back Next >>
Rev Med MD 2013; 4.5 (2)
Diagnosis and treatment of hepatitis C
Álvarez-López F, Castañeda-Huerta ND, Rodríguez-Chávez JL, Segura-Ortega JE, Velarde-Ruiz VJA
Language: Spanish
References: 22
Page: 94-101
PDF size: 652.18 Kb.
ABSTRACT
The viral infections are the most frequent cause of liver cirrhosis in the Mexican population, after the toxicity by alcohol
being the infection by VHC the most common. The infection by hepatitis C virus affects about a 180 million people
worldwide. It is the main cause of chronic hepatitis, cirrhosis and hepatocellular cancer, as well as the first indicator of
liver transplant in the west. This scenario must be thoroughly considered since the need of a liver transplant in this
group of patients could not be feasible particularly for economical reasons. A revision in order to present the information
based on current evidence and accepted about the diagnosis, screening, initial evaluation, general measures, current
pharmacologic treatment as well as contraindications and side effects. Lastly, it includes a section about the new
therapies on chronic infection by hepatitis C virus, since despite the combination of peg-interferon and ribavirin stands
as the standard for the treatment of chronic VHC infection regardless of the genotype, recently has been developed new
medicines and innovative strategies for the treatment of chronic infection VHC genotype 1, since the PR therapy offers
45-70% response rate to genotype 1 compared to the genotype 2 or 3 that reach a 80%.
REFERENCES
1.Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR May 10, 2013 / 62(18);362-365
2.CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR 2012; 61(No. RR-4).
3.Guía de Práctica Clínica, Diagnóstico y Tratamiento de Hepatitis C, México: Secretaria de Salud; 2009.
4.Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1-39.
5.Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004; 140:462-464.
6.Chevaliez S and Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59:1222-1241.
7.Shaheen AA, Wan AF and Myers RP. FibroTest and FibroScan for the prediction of hepatitis Crelated fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102:2589-2600.
8.Shaheen AA and Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912-921.
9.Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Croce LS, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008; 103:2248-2253.
10.Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138- 148.
11.Cheung O and Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008; 12:573-585, viii-ix. 12.Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-290.
13.Seeff LB and Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36:S1-2.
14.Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50:387-392. 15.Aronsohn A and Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol 2009; 43:661-671.
16.Sulkowski M, Lawitz, E, Shiffman, ML, et al. Final results of the ideal (individualized dosing efficacy versus flat dosing to assess optimal pegyalted interferon therapy) phase IIIB study. J Hepatol 2008; 2:S370.
17.Di Bisceglie AM, Ghalib RH and Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007;14:721-729.
18.McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
19.Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, Bellia V, et al. Pegylated interferonalpha2b plus ribavirin: an efficacious and welltolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008; 13:663-673.
20.Rosen H, Chronic Hepatitis C Infection, N Engl J Med 2011, 364; 25.
21.Kwo PY. Boceprevir and Treatment of Chronic Hepatitis C. Clin Liver Dis 2013 63-72.
22.Dabbouseh N.M, Jensen D.M. Future therapies for chronic hepatitis C. Nat Rev Gastroenterology & Hepatology. 10, 26
23.Jazwinski A.B, Muir A.J. Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection. Gastroenterology and Hepatology. Vol 7, March 2011.
24.Barrit A.S., Fried M.W. Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. Gastroenterology 2012; 142:1314-1323
Full text